Speakers

Guest Speaker

The HON Nicola Roxon MP
Minister for Health and Ageing

The Hon Nicola Roxon MP has been the Minister for Health and Ageing since the Labor Government was elected in November 2007. Minister Roxon has been a member of Federal Parliament since 1998, representing the Melbourne western suburbs seat of Gellibrand. Before entering Parliament Minister Roxon was an associate to the nation’s first female High Court Justice, Mary Gaudron, and an industrial lawyer who acted in the high profile waterfront dispute. Minister Roxon has a First Class Honours Law degree and Arts degree from Melbourne University, and graduated top of her law class in 1990. Since becoming Health Minister, she has been busy undertaking crucial reforms to build a better health and hospitals system for the future. Minister Roxon has presided over a 50% increase in health funding for the Nation’s Hospitals; a massive investment in workforce, including a commitment to double the number of GP training places; improving elective surgery capacity and throughput; investment in taking pressure off the Nation’s emergency Departments and the largest single year investment in Preventative Health.

International Speakers

Dr Sean R. Tunis

Dr Sean R. Tunis is the Founder and Director of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP’s main objective is to improve the quality and relevance of clinical research by providing a neutral forum for collaboration among experts, stakeholders and decision makers.

Dr Tunis was a member of the Institute of Medicine Committee on Initial National Priorities for Comparative Effectiveness Research. He advises a wide range of domestic and international public and private health care organisations on issues of comparative effectiveness, evidence based medicine, clinical research, reimbursement and health technology policy.

Through September of 2005, Dr Tunis was the Director of the Office of Clinical Standards and Quality and Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS). He also served as the Director of the Health Program at the Congressional Office of Technology Assessment and as a health policy advisor to the U.S. Senate Committee on Labor and Human Resources.

He received a B.S. degree in Biology and History of Science from the Cornell University School of Agriculture, and a medical degree and masters in Health Services Research from the Stanford University School of Medicine. He is board certified in Internal Medicine and holds adjunct faculty appointments at Johns Hopkins, Stanford and the University of California San Francisco Schools of Medicine.

Professor Kathryn Phillips

Dr Kathryn Phillips is Professor of Health Economics and Health Services Research at the University of California, San Francisco (UCSF) and Founder/Director of the UCSF Center for Translational and Policy Research on Personalised Medicine (TRANSPERS). She is also the Principal Investigator for the TRANSPERS Center, which is a multi-million dollar effort focusing on the translation of personalised medicine into practice and policy. She has appointments in the UCSF Department of Clinical Pharmacy, the UCSF Institute for Health Policy Studies, and the UCSF Comprehensive Cancer Center.

Dr Phillips’ research focuses on the use of quantitative tools to examine policy issues relevant to how healthcare is organised, delivered, and financed in the US. She has served as an adviser to many groups (e.g. Institute of Medicine, President’s Council of Advisors on Science and Technology, GenomeCanada, FDA). She also consults with a number of biotech start-ups, companies, and venture capital firms and serves on the Novartis Molecular Diagnostics Advisory Board.

Dr Phillips holds degrees from the University of California- Berkeley, Harvard, and the University of Texas at Austin and previously spent eight years working for the United States Federal Government.

Dr Steven J. Romano

Dr Steven Romano, MD, is Senior Vice President, Head of Medicines Development Group for Pfizer’s Primary Care Business Unit. He has been in the pharmaceutical industry for over 15 years, and has been involved in all phases of clinical drug development. Recent positions held at Pfizer have included Vice President, Medical Affairs Head for the Primary Care Business Unit and prior to that Development Head, Neurosciences and Vice President, Global Medical, Neuroscience, Pain and Inflammation. He is a board certified psychiatrist and serves on the executive or scientific committees of a number of professional organizations, including the International Society for CNS Clinical Trials and Methodology (ISCTM), on which he currently holds the position of Chair, Scientific Committee.

After receiving his undergraduate degree at Washington University in St. Louis, Dr Romano obtained his medical degree at the University of Missouri, Columbia. He completed his internship, residency in psychiatry, and psychiatry fellowship at The New York Hospital-Cornell Medical Center, New York City and Westchester Divisions. Dr Romano continued on the faculty of Cornell University Medical College for six years prior to joining industry, and was Director of the Outpatient Eating Disorders Clinic and Partial Hospitalization Program at the New York Hospital-Cornell Medical Center-Westchester Division in White Plains, New York. His main areas of focus at Cornell included the treatment and management of anorexia, bulimia, and obesity, and the psychopharmacology of major psychiatric conditions.

Facilitator

Mr Laurie Wilson

Mr Laurie Wilson is President of the National Press Club of Australia and has over 30 years experience in the media as a political journalist, commentator and consultant. Laurie is a contributor to A-PAC, the Australian Public Affairs Channel broadcast by Sky News.

His company, Laurie Wilson and Associates Pty Ltd, was established in 1993 and specialises in strategic communications advice, facilitation and presentation skills training.

He is a graduate in Journalism and Economics (Canberra) and has postgraduate qualifications in Business Administration (Swinburne).

Laurie chaired the two previous Joint Medicines Policy Conferences.

Speaker Profiles

Dr Sean Beggs

Dr Sean Beggs is a paediatrician and paediatric clinical pharmacologist. He currently works at the Royal Hobart Hospital and is a Senior Lecturer at the School of Medicine, University of Tasmania. One of his principle areas of interest is the quality use of medicine in children, including improving their access to appropriate medications, both in Australia and developing countries. He has performed a number of reviews for the WHO’s ‘make medicines child size’ initiative and is a member of the Paediatric Medicines Advisory Group to the Department of Health and Ageing, and to the Pharmaceutical Benefits Advisory Committee.

Ms Carol Bennett

Ms Carol Bennett is the Chief Executive Officer of the Consumers Health Forum of Australia (CHF), the peak organisation for health consumers in Australia. Ms Bennett leads CHF’s work to ensure a strong consumer voice and consumer participation in health reform through advocacy, policy development and consumer research. Safety and quality, access, regulation and funding of therapeutic goods are key interest areas. Ms Bennett has worked at the executive level in health organisations for the last 15 years, including as CEO of peak national and state health bodies, and major consultancy roles with organisations including beyondblue. She has a Masters in Public Policy from the Australian National University.

Ms Karen Carey

Ms Karen Carey is an experienced and respected consumer advocate who works to improve consumer health outcomes by contributing a strong consumer voice to health policy at the national level. She has an extensive understanding of the consumer issues and contextual environment in therapeutic goods regulation and health technology assessment.

Professor Alan Cass

Professor Alan Cass is Senior Director of the Renal and Metabolic Division in the George Institute for Global Health and Professor in the Sydney Medical School, University of Sydney. He is Chief Investigator of the Kanyini Vascular Collaboration and the Inaugural Chair of the Scientific Committee of the Australasian Kidney Trials Network. Alan works with Aboriginal community and health service partners to develop strategies to improve access to health services and to improve health outcomes for people with chronic disease.

Dr Sophie Couzos

Dr Sophie Couzos is a public health physician with 19 years experience working within both Aboriginal community-controlled health services (ACCHSs) and the National Aboriginal Community Controlled Health Organisation (NACCHO), occupying the position of Public Health Medical Officer since 1998. She spent 14 years in remote Australia, with seven years as a GP in the Kimberley region of WA. Within NACCHO, she instigates and influences national policies and programs towards achieving health equity for the Aboriginal population through ACCHSs. She has developed clinical practice guidelines, undertaken award winning research (NACCHO Ear Trial), and is editor and author of Aboriginal Primary Health Care: An evidence-based approach (3rd edition, published by Oxford University Press).

She is an adjunct Associate Professor, James Cook University, School of Public Health and Tropical Medicine, Townsville, Qld.

Mr Malcolm Crompton

Mr Malcolm Crompton is Managing Director of Information Integrity Solutions P/L. He is also the Asia Pacific based Director of the International Association of Privacy Professionals (IAPP). Information Integrity Solutions P/L has advised Australian Government departments and agencies, Australian financial services institutions and many leading global ICT companies on developing trust and delivering privacy to customers.

Mr Crompton was Australia’s Privacy Commissioner for five years until April 2004. He led the implementation of Australia’s private sector privacy law. Between 1996 and 1999, he was Manager of Government Affairs in Canberra for AMP Ltd. In the previous 20 years, he held senior executive positions in the Australian Public Service. He has degrees in Chemistry and Economics.

Professor Philip Davies

Professor Philip Davies was appointed as Professor of Health Systems and Policy in the School of Population Health at the University of Queensland in 2009. Prior to taking up his current position he worked for 6½ years as a Deputy Secretary in the Australian (Federal) Government Department of Health and Ageing where he was responsible for several key areas of health policy and financing as well as corporate management of the Department.

In November 2009 Professor Davies was also elected to the Board of GPpartners, one of Australia’s largest and longest-established Divisions of General Practice.

Mr Will Delaat

Mr Will Delaat has been the Chairman of Medicines Australia, since 2008, following his retirement as Managing Director of Merck Sharp & Dohme (MSD) Australia and Merck’s Regional Director for Australia and New Zealand, a position he held for 11 years. Will has over 35 years experience in the pharmaceutical industry, having held a variety of roles both in Europe and Australia, and across three different multinational companies.

In June 2008, Will was appointed as a Director to the Board of Pharmaxis, a local specialist pharmaceutical company involved in developing therapeutic products for chronic respiratory and autoimmune diseases. In 2010, he was appointed to the Board of Medicines Australia member company, iNova Pty Ltd.

He has an Honours Science degree from London University and a background in sales and marketing and business development.

Ms Jennifer Doggett

Ms Jennifer Doggett is a Fellow of the Centre for Policy Development and a consultant working in the health sector for a number of professional, industry and consumer groups. She has previously worked within the Federal Department of Health, as a political advisor on health issues and for a peak medical organisation. She is the author of A New Approach to Primary Care for Australia and Out of pocket: Rethinking co-payments in health, and a co-author of More than Luck: Ideas Australia needs now.

Mr Bruce Goodwin

Mr Bruce Goodwin is the Managing Director for Janssen Australia & New Zealand, a role he has held since January 2009 having previously been the VP of Sales and Marketing. He has a strong record in talent management and focuses strongly on building greater organisational capabilities and on the accelerated development of key individuals. His career with Johnson & Johnson spans 27 years and includes experience across three countries and multiple functions. He has held Management Board positions in sales and marketing and in finance as well as having gained valuable experience in business development and global portfolio management. His service with Johnson & Johnson outside of Australia has included postings to Janssen Belgium and Janssen-Cilag United Kingdom. Mr Goodwin is a Board Member of Medicines Australia.

Janne Graham AM

Ms Janne Graham has a 30-year history of involvement as a health consumer spokesperson, advocate and representative. She has been awarded membership of the Order of Australia for her services to the health consumer movement and the National Health and Medical Research Council. She has been active in the development, articulation and promotion of the National Medicines Policy within government forums and professional and industry conferences. She currently represents health consumers on national and local (ACT) committees relating to professional standards, health technology and safety and quality issues.

Mr Mendel Grobler

Mr Mendel Grobler is the Director, Patient Access at Pfizer Australia and is responsible for reimbursement strategy for the company’s products in Australia and New Zealand, as well as advising Pfizer Inc. on regional and global approaches to Health Technology Assessment. He has been working in the field of healthcare funding and financing for more than 20 years and also has extensive experience across the pharmaceutical industry including manufacture, product development, registration, distribution and community/hospital pharmacy. He has previously represented the industry on the Economic Sub-Committee of PBAC and also served as adviser to the Australian Department of Veterans’ Affairs.

Ms Jane Halton PSM

Ms Jane Halton is Secretary of the Australian Department of Health and Ageing. She is responsible for all aspects of the operation of the Department including the provision of advice on and administration of Medicare, the Pharmaceutical Benefits Scheme, Aged and Community Care, Population Health, regulation of Therapeutic Goods, plus hospital financing and Private Health Insurance. She also has responsibility for leadership on health security issues, including matters related to bioterrorism.

Ms Halton is a member of the board of the Australian Institute of Health and Welfare, a board member of the National E- ealth Transition Authority and a Commissioner of the Australian Commission on Safety and Quality in Health Care. She is also on the executive board of the Institute for Health Metrics and Evaluation at the University of Washington, on the Advisory Boards of the Centre for Applied Philosophy and Public Ethics (CAPPE), on the Melbourne Institute Advisory Board, and is chair of the OECD’s Health Committee.

Professor Christine Jenkins AM

Professor Christine Jenkins is Clinical Professor of Medicine, Sydney University and Senior Staff Specialist in Thoracic Medicine at Concord Hospital, Sydney. She has a strong clinical and research interest in the management of asthma and COPD and is head of the Airways Group at the Woolcock Institute of Medical Research, Sydney. She chairs the Education program in the Co-operative Research Centre for Asthma and Airways and is actively involved in research translation to primary care and allied health professionals. Professor Jenkins is a member of the GOLD Executive and Chairs the Dissemination and Implementation task group of GOLD and has participated in the formulation of Australian Asthma and COPD clinical guidelines. In 2001 she received an AM in the Order of Australia for services to respiratory medicine, especially as a physician, administrator and educator, in the field of asthma education.

Professor Louisa Jorm

Professor Louisa Jorm is the Foundation Professor of Population Health at the University of Western Sydney. She also holds the position of Principal scientist at the Sax Institute. She is an epidemiologist who has worked in senior roles both in government and academia. Her areas of expertise include data linkage, use of large administrative data sets and facilitating the policy and practice uptake of research. She currently leads the development of the SW/ACT node of the Population Health Research Network (the emerging national infrastructure for data linkage research). In her role at the Sax Institute, professor Jorm is part of the management team for the 45 and Up Study, Australia’s largest study of healthy ageing, which includes 265,000 participants aged 45 years and over from across NSW and incorporates linkage to PBS, MBS and other administrative datasets.

Mr David Learmonth

Mr David Learmonth is a Deputy Secretary with the Department of Health and Ageing. His current portfolio includes Medical Benefits, Pharmaceutical Benefits, Private Health Insurance, Aboriginal and Torres Strait Islander Health, the Queensland State Office and the ACT Office.

Mr Learmonth joined the Australian Department of Health and Ageing in November 2003 as the First Assistant Secretary, Primary Care Division. He was responsible for implementing the Strengthening Medicare Package and for a range of programs including divisions of general practice, GP training, after hours programs, quality, allied health, nursing, GP collaboratives, research and workforce measures.

Professor Andrew J McLachlan

Professor Andrew McLachlan is a pharmacist, academic and researcher with experience in clinical and experimental pharmacology and research into the quality use of medicines. He is Professor of Pharmacy (Aged Care) in the Faculty of Pharmacy at the University of Sydney based at Concord Hospital and the Centre for Education and Research on Ageing (CERA) at Concord Hospital, and is currently the Associate Dean (Research) in the Faculty of Pharmacy, University of Sydney. Previously he served as Associate Dean (Postgraduate) for five years.

Professor McLachlan’s particular expertise is in the field of clinical and experimental aspects of pharmacokinetics and pharmacodynamics.

Professor McLachlan serves as the Inaugural Chair of Australia’s National Medicines Policy Committee and is a member of the Pharmaceutical Subcommittee of the Australian Advisory Committee on Prescription Medicines (ACPM). He is the current president of the Australasian Pharmaceutical Science Association and is a member of the Australian Sports Antidoping Authority. He is a member of the executive of the Commonwealth Pharmacists Association (CPA) representing the Pacific Region.

Dr Ross Maxwell

Dr Ross Maxwell is the prescribing expert on the National Medicines Policy Committee. He is a procedural rural doctor in Dalby, South East Queensland, where he has worked for the last 19 years. He has worked in a number of health organisations during this time, including the Southern Queensland Rural Division of General Practice, the Australian Medical Association and the Rural Doctors Association, and has served as both Queensland and Australian President during this time. Dr Maxwell is currently a member of the Professional Programs and Services Advisory Committee and the Australian Medical Association Rural Reference Group. He was also a member of the board of the National Prescribing Service and is a current board member of Health Workforce Queensland.

Professor Malcolm Parker

Professor Malcolm Parker is Associate Professor of Medical Ethics and Head of the Discipline of Medical Ethics, Law and Professional Practice in the School of Medicine, University of Queensland. He teaches ethics, law and professional issues in the MBBS program. He has qualifications in medicine, philosophy and health law, and was in general medical practice for over 30 years. He chairs UQ’s Human Experimentation Ethical Review Committee, and is a member of the Queensland Health Clinical Ethics Committee and the AMAQ Ethics Committee. He is also a director of the Postgraduate Medical Council of Queensland, and a member of the Health and Performance Committee of the Qld Board of the Medical Board of Australia. He is the current president of the Australasian Association of Bioethics and Health Law, and is a member of the editorial boards of four journals in bioethics, medical law and medical education.

Dr John Primrose

Dr John Primrose joined the (then) Commonwealth Department of Health in 1990 as a Senior Medical Advisor. Since that time, he has worked in the areas of pharmaceutical benefits, rational use of medicines, Medicare benefits and health technology assessment. He is currently Medical Advisor to the Pharmaceutical Benefits Division and is involved in the evaluation of pharmaceuticals for listing on the Pharmaceutical Benefits Scheme, as well as the operational aspects of the Scheme. Dr Primrose graduated with First Class Honours from the University of Sydney in 1978 and underwent postgraduate training in radiation oncology at Royal Prince Alfred and Westmead Hospitals. He was admitted as a Fellow of the Royal Australasian College of Radiologists in 1983. Dr Primrose was a staff specialist at St Vincent’s Hospital from 1983 to 1985 and then Director of Radiation Oncology at Woden Valley Hospital from 1985 to 1990.

Professor Libby Roughead

Professor Libby Roughead’s research interests include public policy concerning medicines, quality use of medicines, pharmacoepidemiology and adverse drug events. She has a future fellowship funded by the Australian Research Council and is co-director of a national prescriber intervention and feedback program targeting Australian general practitioners and veterans. She is currently a member of the Drug Utilisation Sub- Committee of the Pharmaceutical Benefits Advisory Committee, the Medication Safety Reference Group of the Australian Safety and Quality Commission and a Board member of Therapeutic Guidelines Ltd.

Emeritus Professor Lloyd Sansom AO

Professor Lloyd Sansom played a major role in the development of Australia’s National Medicines Policy and is Editor of the Australian Pharmaceutical Formulary and Handbook (APF) and a member of the Editorial Advisory Board of the Australian Medicines Handbook. He has sat on numerous government and industry advisory groups, including the Pharmaceutical Benefits Advisory Committee (Chair 2001–2011).

Professor Sansom’s research interests are in the areas of pharmacokinetics, biopharmaceutics and the quality use of medicines.

Professor Sansom graduated in pharmacy in 1962 and completed his PhD in Biophysical Chemistry at the University of Adelaide in 1972. In 2006 he was awarded honorary doctorate degrees by Newcastle, Griffith and Queensland universities.

The University of South Australia granted Professor Sansom the title of Emeritus Professor in 2001, after serving as a Professor of Pharmacy from 1990 and heading the University’s School of Pharmacy and Medical Sciences from 1995 to 2000. In 2004 the University recognised his significant contributions by naming the Sansom Institute for Health Research in his honour.

Mr Kos Sclavos

Mr Kos Sclavos has been National President of The Pharmacy Guild of Australia since 2005. Before becoming the Guild’s President, he spent nine years as the Queensland Guild Branch President, and six years as National President of the Australian Institute of Pharmacy Management (now ACPPM). He is driving pharmacy’s exciting new IT agenda in eHealth and already has many successes with projects such as Project Stop to track sales of pseudoephedrine and prevent suspicious sales. Mr Sclavos serves on a variety of industry bodies and committees. He has been a driving force behind a number of industry initiatives including the Advanced Diploma of Community Pharmacy Management and the Quality Care Pharmacy Program. In 2008 he was awarded a Doctor of University of Griffith University for his services to pharmacy.

Dr Brendan Shaw

Dr Brendan Shaw has been Chief Executive of Medicines Australia since January 2010. He has been instrumental in guiding the pharmaceutical industry through reforms to the Pharmaceutical Benefits Scheme, the Pharmaceutical Benefits Advisory Committee processes and the Therapeutic Goods Administration. He has driven Medicines Australia’s research program and Medicines Australia’s contribution to the international debate on health technology assessment.

Prior to taking up his appointment with Medicines Australia in January 2004, Dr Shaw was adviser to the then Shadow Minister for Innovation, Industry and Trade, Dr Craig Emerson MP. He has an honours degree in economics from the University of Queensland and a PhD in management from Monash University.

Professor John Turnidge

Professor John Turnidge is Clinical Director of Microbiology and Infectious Diseases for SA Pathology, based at Women’s and Children’s Hospital in Adelaide. He is an Infectious Disease Physician and Microbiologist who has had a long career in Adelaide and Melbourne working with antibiotic resistance and appropriate antibiotic use. Professor Turnidge was inaugural president of the Western Pacific Society of Chemotherapy, and co-founded the Australian Society for Antimicrobials. He has served on the scientific program committees of the Interscience Conference on Antimicrobial Agents and Chemotherapy, and the European Congress for Clinical Microbiology and Infectious Diseases. At a local level, Professor Turnidge has been involved with a range of committees related to the management of antimicrobial resistance, including JETACAR (the Joint Expert Technical Advisory Committee on Antimicrobial Resistance) and the Expert Advisory Group on Antimicrobial Resistance and the Antimicrobial Resistance Advisory Committee of the National Health and Medical Research Council.

Professor Rosalie Viney

Professor Rosalie Viney is Associate Professor of Health Economics and Deputy Director of the Centre for Health Economics Research and Evaluation at the University of Technology, Sydney. She is the Chair of the Economics Sub-Committee of the Pharmaceutical Benefits Advisory Committee and a member of PBAC. She is the team leader for the Cancer Research Economics Support Team at CHERE, which is contracted to provide health economics advice and support to the Cancer Australia Cancer Clinical Trials Groups. She is also a Chief Investigator on the NHMRC Capacity Building Grant which is aimed at building capacity in innovative approaches to health technology assessment.

Dr Rob Walters

Dr Rob Walters is a practising General Practitioner in Hobart. From November 2002 to November 2005, he was the Chair of the Australian Divisions of General Practice (ADGP now AGPN), the national organisation that represented 117 local Divisions of General Practice. He is also a medico-legal adviser and case manager for the Medical Indemnity Protection Society (MIPS) in Tasmania and regularly presents to medical practitioners nationally on matters related to Medical Indemnity and Medicine and the law. He has served and continues to serve on a number of boards and councils representing General Practice including the boards of Headspace, General Practice South, the National Advisory Council on Mental Health, the Beyondblue Clinical Reference Council and DVA’s LMO Advisory Committee. Dr Walters also has an interest in Occupational Medicine and is the Medical Director on the Tasmanian Work Cover Board as well as a past Chair of the Cancer Council of Tasmania.

Professor Robyn Ward

Professor Robyn Ward heads the Prince of Wales Clinical School, University of NSW and is the Director of Area Cancer Services for the South Eastern Sydney and Illawarra Area Health Service. At the same time she leads the adult cancer research program at the Lowy Cancer Research Centre. Her training as a medical oncologist has strongly informed her research objectives, which focus on improving the management of cancer through research, be it in the laboratory, at the bedside, or in the realm of health services research. She has been a longstanding member of the Pharmaceutical Benefits Advisory Committee (PBAC) and in 2009 was appointed the Chair of the Commonwealth Medical Services Advisory Committee.

Deborah Waterhouse

Ms Deborah Waterhouse is the General Manager of GlaxoSmithKline (GSK) Australia and New Zealand and has been with the company since 1996. Her experience is broad, having progressed through increasingly senior positions in Sales, Marketing, Human Resources and Research and Development, in the UK, Europe and Australasia. She became General Manager of GSK Australia and New Zealand in August 2008. Ms Waterhouse believes that it is a privilege and responsibility as a successful company to give back to the community across the world. And that ethical practice is the foundation of everything we do in this industry. GlaxoSmithKline is a global, research-based pharmaceutical and healthcare company with a long, proud history in Australia. Ms Waterhouse is a Board Member of Medicines Australia.

Dr Lynn Weekes

Dr Lynn Weekes is the inaugural Chief Executive Officer of the NPS. She originally trained as a pharmacist, doing her undergraduate degree at Sydney University and going on to practise in community, hospital, policy and research settings. She worked at St Vincent’s Hospital in Sydney before taking up the position of Executive Officer at NSW Therapeutic Assessment Group. She has a strong professional interest in quality assurance, behaviour change and pharmacoepidemiology. Dr Weekes believes her pharmacy training has provided an excellent base for achievement of public health changes as they relate to medicines. She has a MSc in pharmaceutics and a PhD in community medicine.